ocriplasmin
Sign in to saveAlso known as microplasmin
Ocriplasmin, sold under the brand name Jetrea, is a recombinant protease with activity against fibronectin and laminin, components of the vitreoretinal interface. It is used for treatment of symptomatic vitreomacular adhesion, for which it received FDA approval on 17 October 2012. It works by dissolving the proteins that link the vitreous to the macula, resulting in posterior detachment of the vitreous from the retina.
Key facts
- Drug.tradename
- Jetrea
- Drug.licence_EU
- yes
- Drug.pregnancy_AU
- B2
- Drug.routes_of_administration
- Intravitreal
- Drug.ATC_prefix
- S01
- Drug.ATC_suffix
- XA22
- Drug.legal_AU
- S4
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.CAS_number
- 1048016-09-6
- Drug.IUPHAR_ligand
- 7446
- Drug.DrugBank
- DB08888
- Drug.UNII
- 7V6HE3DM5A
- Drug.ChemSpiderID
- none
- Drug.KEGG
- D09646
- Drug.C
- 1214
- Drug.H
- 1890
- Drug.N
- 338
via Wikipedia infobox
~2 min read
Article
5 sectionsContents
- Structure
- Mechanism of action
- FDA regulation
- Sales
- References
Ocriplasmin, sold under the brand name Jetrea, is a recombinant protease with activity against fibronectin and laminin, components of the vitreoretinal interface. It is used for treatment of symptomatic vitreomacular adhesion, for which it received FDA approval on 17 October 2012. It works by dissolving the proteins that link the vitreous to the macula, resulting in posterior detachment of the vitreous from the retina.
== Structure == Ocriplasmin is an injectable drug that is "a truncated form of the human serine protease plasmin." The protease plasmin still retains its enzymatic properties. Ocriplasmin consists of two polypeptide chains that are linked by disulfide bonds. Additionally, the longer peptide chain has four disulfide bonds. Ocriplasmin is only moderately stable when injected, and this is due to autolytic degradation.
Available in 10 languages
via Wikidata sitelinks · CC0